Inari Medical (NARI)
(Delayed Data from NSDQ)
$57.98 USD
+3.18 (5.80%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $58.68 +0.70 (1.21%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$57.98 USD
+3.18 (5.80%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $58.68 +0.70 (1.21%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth B Momentum D VGM
Zacks News
Here's Why You Should Retain Align Technology (ALGN) Stock Now
by Zacks Equity Research
Investors are optimistic about Align Technology (ALGN), led by its strong global presence.
Zimmer Biomet (ZBH) Q3 Earnings Top Estimates, Margins Fall
by Zacks Equity Research
Zimmer Biomet (ZBH) gains from solid strategic execution and increasing traction in innovations in the third quarter.
Myriad Genetics (MYGN) Posts Narrower-Than-Estimate Loss in Q3
by Zacks Equity Research
Myriad Genetics' (MYGN) third-quarter 2023 revenues increase year over year, driven by strong testing volume improvement across all its businesses.
Insulet (PODD) Q3 Earnings Beat, 2023 Sales Growth View Up
by Zacks Equity Research
Insulet's (PODD) third-quarter 2023 revenues increase year over year as a result of continued high demand for Omnipod 5.
Inari Medical, Inc. (NARI) Loses -27.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Inari Medical, Inc. (NARI) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Inari Medical (NARI) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Inari Medical's (NARI) third-quarter results benefit from strong product adoption and geographical performances.
Teleflex (TFX) Q3 Earnings Top Estimates, 2023 Outlook Up
by Zacks Equity Research
Teleflex's (TFX) year-over-year revenue growth was driven by all global product categories in Q3.
Haemonetics (HAE) Q2 Earnings Top Estimates, 2024 View Up
by Zacks Equity Research
The robust volume growth and price benefits in the Plasma business driven by strong momentum in U.S. collections and price benefit Haemonetics' (HAE) fiscal second-quarter results.
Penumbra (PEN) Q3 Earnings Top Estimates, Margins Increase
by Zacks Equity Research
Penumbra's (PEN) vascular and neuro product categories continue to show encouraging growth trends.
Exact Sciences (EXAS) Q3 Earnings Beat, Gross Margin Rises
by Zacks Equity Research
Exact Sciences' (EXAS) Screening revenue upside is primarily attributable to broad-based momentum in Cologuard adoption.
Envista (NVST) Q3 Earnings Miss Estimates, Gross Margin Down
by Zacks Equity Research
Envista's (NVST) Q3 performance is impacted by the negative impact of Russia and the weakness of higher-end specialty procedures in developed markets.
CVS Health (CVS) Q3 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Robust sales growth across all three operating segments drove CVS Health's (CVS) third-quarter results.
IDEXX (IDXX) Q3 Earnings Top Estimates, '23 Sales View Down
by Zacks Equity Research
IDEXX (IDXX) delivers better-than-expected earnings in the third quarter of 2023.
QIAGEN (QGEN) Q3 Earnings and Revenues Beat, Margins Down
by Zacks Equity Research
In an increasingly challenging macro environment, QIAGEN (QGEN) surpasses the earnings and revenue outlook in the third quarter of 2023.
Medical Device Stocks to Watch for Earnings on Nov 1: MCK & More
by Indrajit Bandyopadhyay
Medical Device companies' Q3 results are likely to reflect strength in customer demand. Let's see how MCK, QDEL, GKOS and NARI are placed ahead of their earnings release.
Zacks Industry Outlook Highlights Alcon, STERIS and Inari Medical
by Zacks Equity Research
Alcon, STERIS and Inari Medical are part of the Zacks Industry Outlook article.
Bio-Rad (BIO) Misses Q3 Earnings Estimates, Cuts 2023 View
by Zacks Equity Research
The deterioration in biopharma and early biotech customer spending and a challenging macroeconomic environment in China impact Bio-Rad's (BIO) Q3 performance.
3 Medical Instruments Stocks Countering Industry-Wide Headwinds
by Urmimala Biswas
The Zacks Medical - Instruments industry is being affected by ongoing inflation and a tightening monetary policy. However, the rising demand for digital health offers some respite. ALC, STE and NARI are poised to brave the challenges.
Chemed (CHE) Q3 Earnings and Revenues Surpass, Margins Rise
by Zacks Equity Research
Chemed's (CHE) third-quarter 2023 performance reflects strength in the VITAS segment.
ResMed (RMD) Q1 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
ResMed's (RMD) solid revenue growth in the first quarter of fiscal 2024 reflects the strength of AirSense 10 and AirSense 11 sleep devices and robust growth in the mask product portfolio.
Boston Scientific (BSX) Q3 Earnings Beat, Gross Margin Dips
by Zacks Equity Research
Boston Scientific's (BSX) organic and operational revenues at its respective core business segments and geographies rise in the third quarter.
Edwards Lifesciences (EW) Q3 Earnings Match Mark, Margins Dip
by Zacks Equity Research
Edwards Lifesciences (EW) TMTT performance benefits from the accelerated adoption of the differentiated PASCAL precision platform in the third quarter.
Labcorp (LH) Q3 Earnings and Revenues Beat, Margins Fall
by Zacks Equity Research
Labcorp (LH) delivers a strong performance in the third quarter of 2023 across the Diagnostics Laboratories and Biopharma Laboratory Services businesses.
Integra's (IART) Q3 Earnings Miss Estimates, 2023 View Cut
by Zacks Equity Research
The impact of lost revenues and an increase in the return provision related to the Boston product recall dent Integra's (IART) Q3 revenues.
Amedisys' (AMED) Q3 Earnings Miss Estimates, Margins Up
by Zacks Equity Research
The continuous shortage of clinical labor, nursing in particular, is likely to have impacted Amedisys' (AMED) Q3 performance.